Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.
Company profile
Ticker
TOMDF
Exchange
Website
CEO
Herman Weiss
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Todos Medical USA • Todos Medical Singapore Pte. Ltd. • Breakthrough Diagnostics Inc. • Provista Diagnostics, Inc. ...
TOMDF stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
17 Jul 23
SEC STAFF ACTION
SEC staff action: Order
13 Jun 23
NT 10-Q
Notice of late quarterly filing
16 May 23
8-K
Entry into a Material Definitive Agreement
31 Mar 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
30 Sep 22
8-K
Entry into a Material Definitive Agreement
29 Sep 22
8-K
Entry into a Material Definitive Agreement
13 Sep 22
8-K/A
Entry into a Material Definitive Agreement
12 Sep 22
Latest ownership filings
4
GERALD COMMISSIONG
29 Mar 23
SC 13D/A
Strategic Investment Holdings, LLC
15 Mar 23
SC 13D
Strategic Investment Holdings, LLC
17 Feb 23
4
GERALD COMMISSIONG
24 Aug 22
SC 13G
Leviston Resources LLC
6 Apr 22
SC 13G/A
Strategic Investment Holdings, LLC
1 Nov 21
SC 13G
Strategic Investment Holdings, LLC
24 Sep 21
SC 13G
Geller Avi
15 Sep 21
4
GERALD COMMISSIONG
8 Jul 21
SC 13G
Strategic Investment Holdings, LLC
29 Jun 21
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 57.00 k | 57.00 k | 57.00 k | 57.00 k | 57.00 k | 57.00 k |
Cash burn (monthly) | (no burn) | 9.08 k | 600.67 k | 960.75 k | (no burn) | 316.42 k |
Cash used (since last report) | n/a | 169.14 k | 11.19 mm | 17.89 mm | n/a | 5.89 mm |
Cash remaining | n/a | -112.14 k | -11.13 mm | -17.83 mm | n/a | -5.84 mm |
Runway (months of cash) | n/a | -12.3 | -18.5 | -18.6 | n/a | -18.4 |
Institutional ownership, Q1 2023
8.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.64 mm |
Total shares | 246.98 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Strategic Investment | 78.60 mm | $63.00 k |
Leviston Resources | 76.96 mm | $1.74 mm |
Geller Avi | 67.42 mm | $2.56 mm |
Healthcare 365 Tech | 24.00 mm | $1.27 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 23 | Gerald Commissiong | Ordinary Shares | Buy | Acquire P | No | No | 0.0009 | 5,000,000 | 4.50 k | 7,055,680 |